摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氨基-5-溴苯甲醛 | 29124-57-0

中文名称
2-氨基-5-溴苯甲醛
中文别名
——
英文名称
2-amino-5-bromobenzaldehyde
英文别名
——
2-氨基-5-溴苯甲醛化学式
CAS
29124-57-0
化学式
C7H6BrNO
mdl
——
分子量
200.035
InChiKey
VBYZWJMZASVGNB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    75-77°
  • 沸点:
    290.3±25.0 °C(Predicted)
  • 密度:
    1.673

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    43.1
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 危险等级:
    IRRITANT
  • 海关编码:
    2922399090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    温度控制在2-8°C,并置于惰性气体氛围中。

SDS

SDS:73ebaa8c21fb881e7704d13723f38fbf
查看
Material Safety Data Sheet

Section 1. Identification of the substance
2-Amino-5-bromobenzaldehyde
Product Name:
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

Section 3. Composition/information on ingredients.
2-Amino-5-bromobenzaldehyde
Ingredient name:
CAS number: 29124-57-0

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H6BrNO
Molecular weight: 200

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-氨基-5-溴苯甲醛对甲苯磺酸溶剂黄146 作用下, 以 N,N-二甲基甲酰胺甲苯 为溶剂, 反应 22.0h, 生成 10-cyano-(20S)-camptothecin
    参考文献:
    名称:
    植物抗肿瘤剂。30.新型喜树碱类似物的合成和结构活性。
    摘要:
    已经制备了具有许多环A取代基的20S,20RS和20R构型的大量喜树碱(CPT)类似物。拓扑异构酶I(TI)抑制数据(IC50)已通过标准程序获得。通常,具有20S构型的化合物在9或10位上被氨基,卤代或羟基取代会导致TI抑制作用增强。20RS构型的化合物在体外和体内活性较低,而20R构型的化合物则无活性。在TI抑制试验中,在A环上具有10,11-亚甲二氧基取代的化合物显示出显着的效能增强。在包括L-1210小鼠白血病测定法在内的各种体内测定法中确定的某些类似物的活性通常与TI抑制作用一致。制备了许多水溶性类似物,例如20-甘氨酸酯,9-甘氨酰胺或水解的内酯盐,并在体外和体内试验中进行了测试。通常,就L-1210分析中的TI抑制作用和寿命延长而言,这些化合物的活性均不如CPT。然而,某些20-甘氨酸酯在静脉内给药后显示出良好的体内活性。
    DOI:
    10.1021/jm00070a013
  • 作为产物:
    描述:
    4-溴-2-硝基苯甲醛盐酸铁粉 作用下, 以 乙醇 为溶剂, 反应 1.5h, 生成 2-氨基-5-溴苯甲醛
    参考文献:
    名称:
    [EN] BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES
    [FR] PYRROLINE-CARBOXY-LYSINE PRODUITE PAR BIOSYNTHÈSE ET MODIFICATIONS DE PROTÉINES SPÉCIFIQUES DE SITE OBTENUES PAR UNE DÉRIVATISATION CHIMIQUE DE PYRROLINE-CARBOXY-LYSINE ET DE RÉSIDUS DE PYRROLYSINE
    摘要:
    本文披露了吡咯酮羧基赖氨酸(PCL),一种吡咯赖氨酸类似物,它是一种天然的、生物合成产生的氨基酸,以及生物合成生成PCL的方法。本文还披露了含有PCL的蛋白质、多肽和肽以及将PCL纳入这些蛋白质、多肽和肽中的方法。本文还披露了具有PCL或吡咯赖氨酸的蛋白质、多肽和肽的特定位点衍生化。本文还披露了具有PCL或吡咯赖氨酸的蛋白质、多肽和肽的交联。
    公开号:
    WO2010048582A1
点击查看最新优质反应信息

文献信息

  • FIBROSIS INHIBITOR
    申请人:Sumitomo Pharmaceuticals Company, Limited
    公开号:EP1479384A1
    公开(公告)日:2004-11-24
    Medicament being useful as a fibrosis inhibitor for organs or tissues, which comprises a compound of the formula (I): wherein Ring Z is optionally substituted pyrrole ring, etc.; W2 is -CO-, -SO2-, optionally substituted C1-C4 alkylene, etc.; Ar2 is optionally substituted aryl, etc.; W1 and Ar1 mean the following (1) and (2): (1) W1 is optionally substituted C1-C4 alkylene, etc.; Ar1 is optionally substituted bicyclic heteroaryl having 1 to 4 nitrogen atoms as ring-forming atoms: (2) W1 is optionally substituted C2-C5 alkylene, optionally substituted C2-C5 alkenylene, etc.; and Ar1 is aryl or monocyclic heteroaryl, which is substituted by carboxyl, alkoxycarbonyl, etc. at the ortho- or meta-position thereof with respect to the binding position of W1, or a pharmaceutically acceptable salt thereof.
    药物作为器官或组织的纤维化抑制剂而有用,包括具有以下式(I)的化合物: 其中环Z是可选择取代的吡咯环等;W2是-CO-,-SO2-,可选择取代的C1-C4烷基等;Ar2是可选择取代的芳基等;W1和Ar1表示如下(1)和(2): (1)W1是可选择取代的C1-C4烷基等;Ar1是可选择取代的具有1至4个氮原子作为环形成原子的双环杂芳基: (2)W1是可选择取代的C2-C5烷基,可选择取代的C2-C5烯基等;以及 Ar1是芳基或单环杂芳基,其在相对于W1的结合位置的邻位或间位处被羧基,烷氧羰基等取代, 或其药学上可接受的盐。
  • [EN] 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES<br/>[FR] 2 -ARYLAMINOQUINAZOLINES DESTINÉES AU TRAITEMENT DES MALADIES PROLIFÉRATIVES
    申请人:NOVARTIS AG
    公开号:WO2009153313A1
    公开(公告)日:2009-12-23
    The invention provides novel compounds that are inhibitors of PDKI. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or composition.
    这项发明提供了一种抑制PDKI的新型化合物。还提供了包括这些化合物的药物组合物,以及使用这些化合物或组合物治疗增殖性疾病,如癌症的方法。
  • One-Pot Allan-Robinson/Friedländer Route to Chromen-/Quinolin-4-ones through the Domino Acetylative Cyclisation of 2-Hydroxy-/2-Aminobenzaldehydes
    作者:Vijai K. Rai、Fooleswar Verma、Ganeshwar P. Sahu、Manorama Singh、Ankita Rai
    DOI:10.1002/ejoc.201701435
    日期:2018.1.31
    A domino reaction between 2‐hydroxy‐/2‐aminobenzaldehydes and α‐haloketones gives chromen‐4‐ones and quinolin‐4‐ones in good to excellent yields. This method represents a new extension of the Allan–Robinson and Friedländer reactions, and uses N‐heterocyclic‐carbene catalysis. This approach has the advantages of operational simplicity, ambient reaction conditions, and no by‐product formation.
    2-羟基/ 2-氨基苯甲醛与α-卤代酮之间的多米诺反应使chromen-4-ones和quinolin-4-ones的产率高到极好。该方法代表了Allan-Robinson和Friedländer反应的新扩展,并使用了N-杂环-卡宾催化。这种方法的优点是操作简单,环境反应条件好,并且不会形成副产物。
  • Identification of Inhibitors of Cholesterol Transport Proteins Through the Synthesis of a Diverse, Sterol‐Inspired Compound Collection
    作者:Thomas Whitmarsh‐Everiss、Asger Hegelund Olsen、Luca Laraia
    DOI:10.1002/anie.202111639
    日期:2021.12.13
    A general strategy for the identification of selective cholesterol transport protein inhibitors through the synthesis of a diverse sterol-inspired compound collection is presented. Fusion of a primary sterol scaffold to diverse secondary natural product-derived scaffolds afforded hits against all of the Aster family of cholesterol transport proteins and selective inhibitors of Aster-C.
    介绍了通过合成多种甾醇化合物集合来鉴定选择性胆固醇转运蛋白抑制剂的一般策略。初级甾醇支架与多种次级天然产物衍生支架的融合提供了针对胆固醇转运蛋白的所有 Aster 家族和 Aster-C 的选择性抑制剂的攻击。
  • Repurposing an Aldolase for the Chemoenzymatic Synthesis of Substituted Quinolines
    作者:Douglas J. Fansher、Richard Granger、Satinderpal Kaur、David R. J. Palmer
    DOI:10.1021/acscatal.1c01398
    日期:2021.6.18
    Quinoline derivatives are important natural products and pharmaceuticals, but their synthesis can be challenging due to poor yields, harsh reaction conditions, and instability of starting materials. Here we report the chemoenzymatic synthesis of quinaldic acids under mild conditions using an aldolase, trans-o-hydroxybenzylidenepyruvate hydratase-aldolase (NahE, or HBPA). A series of 2-aminobenzaldehydes
    喹啉衍生物是重要的天然产物和药物,但由于收率低、反应条件苛刻和起始材料不稳定,它们的合成具有挑战性。在这里,我们报告了使用醛缩酶、反式-o-羟基亚苄基丙酮酸水合酶-醛缩酶(NahE 或 HBPA)在温和条件下化学酶法合成喹哪二酸。在 NahE 存在下,一系列源自相应硝基类似物还原的 2-氨基苯甲醛与丙酮酸反应,以高达 93% 的分离产率得到取代的喹啉。该反应不同于体内NahE 催化的羟醛缩合,而是类似于由其同源物二氢吡啶二羧酸合酶催化的杂环形成。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐